A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

NCT01449461 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large-Cell, Anaplastic
Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Brigatinib

Sponsor

Ariad Pharmaceuticals